ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $864 | -47.1% | 40,383 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $1,633 | -13.3% | 40,383 | -0.2% | 0.00% | -20.0% |
| Q4 2022 | $1,883 | -99.9% | 40,483 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $2,100,000 | +10.0% | 40,483 | +0.2% | 0.01% | 0.0% |
| Q2 2022 | $1,909,000 | -33.4% | 40,383 | +0.2% | 0.01% | -16.7% |
| Q1 2022 | $2,867,000 | -4.8% | 40,283 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $3,012,000 | +30.3% | 40,283 | -1.0% | 0.01% | +20.0% |
| Q3 2021 | $2,311,000 | +26.6% | 40,683 | -1.9% | 0.01% | +25.0% |
| Q2 2021 | $1,826,000 | -13.7% | 41,483 | -3.3% | 0.00% | -20.0% |
| Q1 2021 | $2,115,000 | +15.3% | 42,883 | -1.6% | 0.01% | +25.0% |
| Q4 2020 | $1,835,000 | -8.0% | 43,583 | 0.0% | 0.00% | -20.0% |
| Q3 2020 | $1,995,000 | -10.7% | 43,583 | -2.0% | 0.01% | -16.7% |
| Q2 2020 | $2,233,000 | -2.6% | 44,483 | -0.2% | 0.01% | -14.3% |
| Q1 2020 | $2,293,000 | -22.3% | 44,583 | -6.7% | 0.01% | 0.0% |
| Q4 2019 | $2,952,000 | +26.4% | 47,783 | +22.9% | 0.01% | +16.7% |
| Q3 2019 | $2,336,000 | -30.0% | 38,875 | -1.8% | 0.01% | -25.0% |
| Q2 2019 | $3,339,000 | -13.0% | 39,575 | -1.5% | 0.01% | -20.0% |
| Q1 2019 | $3,838,000 | +35.2% | 40,175 | +0.3% | 0.01% | +25.0% |
| Q4 2018 | $2,838,000 | -16.8% | 40,065 | +0.4% | 0.01% | 0.0% |
| Q3 2018 | $3,410,000 | -26.1% | 39,899 | +0.3% | 0.01% | -27.3% |
| Q2 2018 | $4,612,000 | +43.3% | 39,790 | 0.0% | 0.01% | +37.5% |
| Q1 2018 | $3,219,000 | +42.5% | 39,790 | +3.4% | 0.01% | +60.0% |
| Q4 2017 | $2,259,000 | +25.4% | 38,490 | 0.0% | 0.01% | +25.0% |
| Q3 2017 | $1,801,000 | +31.1% | 38,490 | +0.8% | 0.00% | 0.0% |
| Q2 2017 | $1,374,000 | +16.8% | 38,190 | 0.0% | 0.00% | +33.3% |
| Q1 2017 | $1,176,000 | -8.1% | 38,190 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,279,000 | +26.1% | 38,190 | +0.3% | 0.00% | 0.0% |
| Q3 2016 | $1,014,000 | +10.1% | 38,090 | -8.9% | 0.00% | +50.0% |
| Q2 2016 | $921,000 | -24.9% | 41,790 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $1,227,000 | +47.5% | 41,790 | +65.9% | 0.00% | +50.0% |
| Q4 2015 | $832,000 | +31.6% | 25,190 | +44.0% | 0.00% | 0.0% |
| Q3 2015 | $632,000 | – | 17,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |